Alnylam Pharmaceuticals Discontinues Revusiran Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 226.19 +1.09 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $225.10 | 52 Week High | $109.10 | |||
| Open | $224.92 | 52 Week Low | $31.38 | |||
| Day High | $226.34 | P/E | N/A | |||
| Day Low | $223.76 | EPS | $-1.45 | |||
| Volume | 18,298 | |||||
